NEW YORK (
) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.
Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 4.7%. Since the same quarter one year prior, revenues rose by 11.8%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
- VASC has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 2.59, which clearly demonstrates the ability to cover short-term cash needs.
- The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry average. The net income increased by 11.6% when compared to the same quarter one year prior, going from $1.71 million to $1.91 million.
- Net operating cash flow has increased to $3.07 million or 10.98% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of -22.15%.
Vascular Solutions, Inc., a medical device company, develops solutions for interventional cardiologists and interventional radiologists worldwide. The company has a P/E ratio of 18.6, below the average health services industry P/E ratio of 19 and above the S&P 500 P/E ratio of 17.7. Vascular has a market cap of $185.6 million and is part of the
industry. Shares are up 2% year to date as of the close of trading on Tuesday.
You can view the full
or get investment ideas from our
-- Written by a member of TheStreet RatingsStaff